• Spearheaded the innovative design and development of cutting-edge mRNA constructs aimed at addressing acute and chronic medical challenges, including Familial Hypertriglyceridemia (FTG), Type 2 Diabetes, Non-Alcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease (NAFLD), cardiac dysfunction, and Rare Diseases.• Program leadership and collaborative expertise1. Led two pivotal internal programs, driving the discovery and identification of Lipid Nanoparticle (LNP) encapsulated mRNA formulations with a profound focus on delivery to Hematopoietic Stem and Progenitor Cells (HSPCs). Collaboratively pioneered the utilization of the "humanized NOG" mouse model from Taconic, revolutionizing the assessment of LNP-based therapies.2. Pioneered the identification of a novel animal model, positioned as a groundbreaking alternative to Non-Human Primates (NHPs), for the comprehensive study of LNP encapsulated mRNA biodistribution and expression profiles. This innovation significantly enhanced efficiency and ethical considerations in biodistribution studies.• Provided pivotal support to an array of internal Rare Disease pre-clinical and clinical programs, encompassing Relaxin, VEGF-A, MMA, OTC, PKU, and PA. Notably, played a critical role in refining study designs and conducting meticulous data analyses that substantially bolstered Investigational New Drug (IND) application preparations.

• Managed bioanalytical group: Developed internal assays to support Pre-clinical, Clinical and internal platform Studies.• Designed in vivo and in vitro ADME assays for mRNA Drug product and delivery system to support IND filings.• Toxicology project lead on 1 vaccine program and 1 rare disease programo Designed in vivo tox studies to support Development programs to determine the NOAEL to support IND filing• DMPK project lead on 2 Rare Disease programs. o Worked with Toxicologists developing IND supporting studies.o Worked with CMC to deliver Drug product to CRO’s for validation and assay qualification prior to study start.

•Managed, trained and supported Global compound design and ordering system.•Performed detailed scientific Mode of Inhibition studies on novel bacterial topoisomerase inhibitor AZD0914 to support Phase II Clinical progression. Presented these results at the annual international Infection conference, ICAAC 2014.•Supported Phase I and Phase II Clinical Project: Detailed Mechanistic studies on novel DNA gyrase inhibitor AZD0914 (Phase1), in vitro target profiling for beta-lactamase inhibitor Avibactam (11 enzyme panel) that supported regulatory documentation for Phase II progression.•Developed and revised the standard operating procedures (SOPs) for radiation work, resulting in a decrease in experimental errors and increase in laboratory safety, health and environment.•Implemented an Infection-wide independent summer intern research program and developed successful research proposals for two summer intern students that resulted in contributions to two drug discovery programs.

•Selected Lead for Infection BioScience representative for the department that aided in creating the design, implementation and training for a global compound design and ordering system. Utilized by all scientist globally, enabling them to work more efficiently by streamlining compound ordering and testing.•Analyzed and characterized multiple early-stage drug discovery targets, from various metabolic pathways.•Enabled project transitions across drug discovery process through Hit Evaluation, Lead Optimization, including Lead Identification.•Performed detailed Mechanism of Inhibition studies with Beta-lactamase inhibitors, topoisomerases, and many others.•Selected as representative, In-lab expert on Safety, Health and Environment subject matters including hazard waste disposal, PPE and training requirements and orient new employee to laboratory specifics of site and safety policy.•Organized summer internship program and engagement seminars for enabling summer student to learn about all aspects of early and late drug discovery, end of internship participants internally presented a poster and/or presentation about work.

•Developed and validated a filtration assay that monitored the effect of potential drug candidate’s ability to bind to the human ether-a-go-go (hERG) ion channel to expedite decisions around compound series and aide in building structure activity relationship.•Created standard operating procedures (SOPs) for high-throughput screening and hit evaluation follow-up.•Designed and transferred of enzymatic assay locally and globally – assess customer capabilities and requirements, and performed basic statistical analysis of data.•Enabled several project transitions across drug discovery process from Hit Evaluation, to Lead Optimization, and finally to Lead Identification.•Selected as in-lab expert on Radiation Safety – Monitored, maintained and trained laboratory individuals on our site isotope requirements, protection, and usage.

•Design, execution, and analysis of In vitro dose response experiments•Biophysical characterization of enzymes including assay development (optimization of reaction conditions vary salt, buffer, temperature, surfactants)

•Managed laboratory notebooks and maintained laboratory SOP’s for undergraduate and graduate research students•Aided in graduate and undergraduate research work; cell culture, western blotting, cloning, protein purification, quantification and storage, as well as making protein and DNA gels for routine analysis. •Maintained laboratory equipment, cleaning and calibration of microscopes, scales, pH meters, and pipettes•Prepared reagents and buffers according to Laboratory SOP for general usage•Organized laboratory inventory, purchased and maintained general reagent stocks